Fused tricyclic heterocyclic compounds as hiv integrase inhibitors

A compound having the formula:

• and pharmaceutically acceptable salts thereof,
• wherein:
• A is C1-C4 alkylene, C2-C4 alkenylene, arylene, C3-C7 cycloalkyl, 5 or 6-membered monocyclic heteroaryl, 4 to 7-membered heterocycloalkyl, —O—, —NH—C(O)—, —C(O)NH— or —C(O)—;
• X is O, —N(C1-C6 alkyl)- or —C(R10)(R11), such that when X=O or —N(C1-C6 alkyl)-, then R4, R5, R6 and R7 are each other than —OR9, —N(R9)2 or halo;
• each occurrence of m is independently 0 or 1;
• n is 0 or 1, such that when n is 0, then R4 and R5 are not present;
• R1 is C1-C6 alkyl, which is optionally substituted with up to 3 groups, each independently selected from C3-C7 cycloalkyl, 5 or 6-membered monocyclic heteroaryl, 4 to 6-membered monocyclic heterocycloalkyl, C6-C10 aryl, halo, C1-C6 haloalkyl, —OR9, —N(R9)2, —C(O)R9, — C(O)N(R9)2, —NHC(O)R9 and —SR9, wherein said C3-C7 cycloalkyl group, said 5 or 6-membered monocyclic heteroaryl group, said 4 to 6-membered monocyclic heterocycloalkyl group and said C6-C10 aryl group can each be optionally and independently substituted with one or more groups, each independently selected from C1-C6 alkyl, C3-C7 cycloalkyl, 5 or 6-membered monocyclic heteroaryl, 4 to 6-membered monocyclic heterocycloalkyl, C6-C10 aryl, halo, C1-C6 haloalkyl, —OR9, —N(R9)2, —C(O)R9, —C(O)N(R9)2, —NHC(O)R9 and —SR9;
• R2, R5, R6, R7, R10 and R11 are each independently selected from H, C1-C6 alkyl, C3-C7 cycloalkyl, halo, C1-C6 haloalkyl, —OR9, —N(R9)2, —C(O)R9, —C(O)N(R9)2 and —NHC(O)R9, wherein said C1-C6 alkyl group can be optionally substituted with one or more groups, each independently selected from halo, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —SH or —S(C1-C6 alkyl);
• R3 is H, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 haloalkyl, —C(O)R9, —C(O)N(R9)2 and —NHC(O)R9, wherein said C1-C6 alkyl group can be optionally substituted with one or more groups, each independently selected from halo, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —SH or —S(C1-C6 alkyl);
• R4 is H, or R4 and R5 and the common carbon atom to which they are attached, join to form an endocyclic —C(O)— group;
• R8 is selected from C1-C6 alkyl, —(C1-C3 alkylene)m-(C3-C7 cycloalkyl), —(C1-C3 alkylene)m-(5 or 6-membered monocyclic heteroaryl), —(C1-C3 alkylene)m-(4 to 6-membered monocyclic heterocycloalkyl) and —(C1-C3 alkylene)m-(C6-C10 aryl), wherein said C3-C7 cycloalkyl group, said 5 or 6-membered monocyclic heteroaryl group, said 4 to 6-membered monocyclic heterocycloalkyl group and said C6-C10 aryl group can each be optionally and independently substituted with up to 5 groups, each independently selected from C1-C6 alkyl, C3-C7 cycloalkyl, 5 or 6-membered monocyclic heteroaryl, 4 to 6-membered monocyclic heterocycloalkyl, C6-C10 aryl, halo, C1-C6 haloalkyl, —OR9, —N(R9)2, —C(O)R9, —C(O)N(R9)2, —NHC(O)R9 and —SR9;
• and
• each occurrence of R9 is independently selected from H, C1-C6 alkyl, C3-C7 cycloalkyl, C6-C10 aryl and benzyl.